Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02291's PB Ratio is ranked better than 55.64% of 780
companies
in the Medical Devices & Instruments industry
Industry Median: 2.135
vs HKSE:02291: 1.88
During the past 12 months, Lepu Scientech Medical Technology (Shanghai) Co's average Book Value Per Share Growth Rate was 5.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 52.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Lepu Scientech Medical Technology (Shanghai) Co was 96.20% per year. The lowest was 4.90% per year. And the median was 78.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lepu Scientech Medical Technology (Shanghai) Co PB Ratio Related Terms
Lepu Scientech Medical Technology (Shanghai) Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Scientech Medical Technology (Shanghai) Co PB Ratio Chart
Lepu Scientech Medical Technology (Shanghai) Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Scientech Medical Technology (Shanghai) Co PB Ratio vs Medical Devices & Instruments Industry
Lepu Scientech Medical Technology (Shanghai) Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) has a PB Ratio of 1.88 as of Aug. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. This is 44% below median its historical median of 3.34. Over the past decade, Lepu Scientech Medical Technology (Shanghai) Co's PB Ratio has ranged from 1.35 to 21.47. According to the industry distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #346 out of 780 companies in the Medical Devices & Instruments industry, placing it in the top 44.4%.
Is Lepu Scientech Medical Technology (Shanghai) Co's PB Ratio too high?
Lepu Scientech Medical Technology (Shanghai) Co's current PB Ratio of 1.88 is 44% below median its 10-year median of 3.34. Over the past 10 years, this metric has ranged from a low of 1.35 to a high of 21.47. The Medical Devices & Instruments industry median PB Ratio is 2.14. Lepu Scientech Medical Technology (Shanghai) Co's value of 1.88 is 11.9% below this industry median. Based on the distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #346 out of 780 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Lepu Scientech Medical Technology (Shanghai) Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lepu Scientech Medical Technology (Shanghai) Co's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #346 out of 780 companies for PB Ratio. This puts Lepu Scientech Medical Technology (Shanghai) Co in the upper half of its industry. The industry median PB Ratio is 2.14. Lepu Scientech Medical Technology (Shanghai) Co's value of 1.88 is 11.9% below this benchmark. Historically, Lepu Scientech Medical Technology (Shanghai) Co's own PB Ratio has ranged from 1.35 to 21.47 over the past decade. While the company's 10-year median is 3.34 vs. the industry median of 2.14, Lepu Scientech Medical Technology (Shanghai) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.14, based on 780 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lepu Scientech Medical Technology (Shanghai) Co's current PB Ratio of 1.88 is 11.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lepu Scientech Medical Technology (Shanghai) Co's current PB Ratio is 1.88, which is 44% below median its own 10-year median of 3.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Scientech Medical Technology (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$44.29, compared to a current price of HK$12.18 — trading 72.5% below its estimated fair value. The current PB Ratio is 1.88, which is 44% below median its 10-year median of 3.34 and 11.9% below the Medical Devices & Instruments industry median of 2.14. Lepu Scientech Medical Technology (Shanghai) Co's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291), the current PB Ratio is 1.88 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co stock appears to be undervalued.
The current stock price of HK$12.18 is trading 72.5% below its estimated GF Value™ of HK$44.29.
GuruFocus considers Lepu Scientech Medical Technology (Shanghai) Co to be Significantly Undervalued.
Key valuation signals for HKSE:02291:
PB Ratio: 1.88 (44% below median its 10-year median of 3.34)
GF Value™: HK$44.29 vs. price of HK$12.18 (72.5% below fair value)
Industry Position: 11.9% below the Medical Devices & Instruments median (#346 of 780)
No single metric tells the full story. See the HKSE:02291 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Scientech Medical Technology (Shanghai) Co Ltd is focused on the research and development, manufacture, and commercialization of heart disease interventional medical devices. The reporting segments of the Group are as follows: The Occluder business segment and The heart valve business segment. The company generates majority of its revenue from the Occluder segment which is engaged in the research and development, manufacturing and sales of interventional treatment series occluders for the defective congenital heart disease.
76GF Score
Get the complete analysis for HKSE:02291
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02291 has been successfully added to your 
